Date:1/28/2010

12,768 16,648 -------- -------- Total current liabilities 57,630 57,355 Long-term deferred service revenue 20,810 16,782 Other long-term liabilities 595 848 -------- -------- Total liabilities 79,035 74,985 Stockholders' equity: Total stockholders' equity 242,304 233,557 -------- -------- Total liabilities and stockholders' equity $321,339 $308,542 ======== ======== (1) Information derived from our December 31, 2008 audited Consolidated Financial Statements. Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (In thousands, except per share data, unaudited) Three months ended December 31, September 30, December 31, 2009 2009 2008 ----------------- ----------------- ----------------- Earnings Earnings Earnings per per per Net share- Net share- Net share- income diluted income diluted income diluted ------ -------- ------ -------- ------ -------- GAAP $557 $0.02 $854 $0.03 $3,323 $0.10 Non-GAAP Adjustments: ASC 718  adjustment (a)
'/>"/>

SOURCE Omnicell, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
2. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results